Interaction of sotigalimab with CD40 triggers the cellular proliferation and activation of APCs, including B lymphocytes, dendritic cells, macrophages, and monocytes, leading to the generation of both T cell–dependent as well as humoral immune responses against tumor cells. This evidence concerns the gene CD40 and neoplasm.